Medical News

RSS

Phase III PRIMA study data of Rituxan to be featured at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec today announced data from the Phase III PRIMA study.

21 May 2010

AFSPP program reduces suicide rates

The U.S. Air Force Suicide Prevention Program (AFSPP) has reduced suicide rates significantly since it was launched in 1996, according to a new study that examined almost three decades of data.

21 May 2010

Prescribing practices for dementia patients

Demented patients are often treated nonspecifically with psychoactive medications. Neuroleptic drugs are given even when they are not specifically indicated, as Tomislav Majic and his colleagues from the Charit- Hospital, Berlin, show in the current issue of Deutsches -rzteblatt International.

21 May 2010

Prodigy Diabetes Care honored with Export Achievement Certificate

U.S. Deputy Commerce Secretary Ro Khanna honored Prodigy Diabetes Care, LLC with its Export Achievement Certificate today during a stop in Charlotte aimed at touting President Obama's national export initiative.

21 May 2010

Online health and wellness resource for libraries, educational institutions

A.D.A.M., Inc., a leading provider of consumer health information, benefits technology solutions and online education resources, today announced the availability of Well-Connected, its online health and wellness subscription-based product for the public library and information dissemination markets, featuring enhanced functionalities and user-friendly interfaces for library patrons.

21 May 2010

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Results of two Phase II trials evaluating ALIMTA (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung cancer will be presented by Eli Lilly and Company at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago, Ill., on June 6, 2010.

21 May 2010

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.

21 May 2010

Vesicoureteral reflux more common among girls

Children with vesicoureteral reflux (VUR), in which urine flows backwards into the kidneys from the bladder, have been treated in the past with surgery or antibiotic therapy.

21 May 2010

Volcano reports successful completion of cases with second generation OCT catheter and system

Volcano Corporation announced today the successful completion of Optical Coherence Tomography (OCT) cases with Volcano's second generation OCT catheter and system. Pending IDE approval, Volcano plans to use this OCT system in the US and South America as part of VOILA, a U.S. regulatory trial during 2010. Commercial release of Volcano's OCT system is expected in Europe in early 2011 and in the U.S. in mid-2011.

21 May 2010

Clinical Infectious Diseases journal examines new scientific advances to curb HIV, TB epidemics

As US policymakers consider scaling back on its historic initiative to fight AIDS around the world and downsizing goals to combat tuberculosis, next-generation treatment and prevention strategies to significantly reduce the spread of HIV/AIDS and tuberculosis are now imminent. New science can dramatically change the trajectory of both deadly epidemics, according to a special new issue of the journal Clinical Infectious Diseases.

21 May 2010

Americans divided over nation’s drug approval process

Nearly three-quarters of Americans are confident in our system for reviewing the effectiveness and safety of new medicines and medical devices, yet 41% say it takes too long to approve a drug and allow it to be sold to consumers.

21 May 2010

Infinity to present data from Hsp90 chaperone and Hedgehog pathway inhibitor programs at 2010 ASCO

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that data from its Hsp90 chaperone and Hedgehog pathway inhibitor programs will be presented during the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Ill. from June 4 through June 8, 2010.

21 May 2010

VIA-2291 can reduce inflammation in patients with atherosclerosis: Study

The results of a major clinical study carried out at the Montreal Heart Institute by Dr. Jean-Claude Tardif are now available in the journal Circulation Cardiovascular Imaging. Dr. Tardif is a cardiologist and director of the MHI Research Centre, as well as a professor in the faculty of medicine and holder of the atherosclerosis research chair at the Universit- de Montr-al.

21 May 2010

Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

Exelixis, Inc. today reported promising interim data from an ongoing phase 2 trial of XL184 in patients with recurrent glioblastoma (GB), the most common and aggressive form of brain cancer. Dr. Patrick Wen from the Dana Farber Cancer Institute in Boston, MA will present the data in an Oral Session (Abstract #2006) on Saturday, June 5 at 5:00 p.m. at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

More than 44% Canadian seniors living in residential care homes diagnosed with depression: CIHI study

More than two in five (44%) Canadian seniors living in residential care homes are diagnosed with or have symptoms of depression, according to a new study released today by the Canadian Institute for Health Information.

21 May 2010

Salix announces additional intellectual property protection for rifaximin in treatment of IBS

Salix Pharmaceuticals, Ltd. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,718,608. This patent provides protection until August 2019 for rifaximin, which Salix markets in the United States under the trade names XIFAXAN® (200mg) and XIFAXAN550™ (550mg).

21 May 2010

Restaurant Health Care Alliance launched to help restaurant employees gain access to health care coverage

The National Restaurant Association and UnitedHealthcare are launching the Restaurant Health Care Alliance, offering a suite of products that will help nearly 13 million restaurant employees gain easier access to health care coverage and related products and services. Today, 4 million to 6 million of the nation's nearly 13 million food service industry employees are uninsured at any given time.

21 May 2010

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

Lilly released results today from a Phase II study evaluating Lilly Oncology's tasisulam, a novel anti-cancer agent, in patients with metastatic melanoma, the deadliest form of skin cancer. Study results will be presented during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. on June 6, 2010.

21 May 2010

MSCRF awards grants to 42 projects under Maryland Stem Cell Research Act of 2006

The Maryland Stem Cell Research Commission has completed its evaluation of the 141 applications in response to its three official Requests for Applications during the FY 2010 funding cycle. The board of directors of the Maryland Technology Development Corporation reviewed the Commission's recommendations and approved 42 projects totaling $11.7 million in funding through the Maryland Stem Cell Research Fund under the Maryland Stem Cell Research Act of 2006.

21 May 2010

ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting

ZymoGenetics, Inc. announced that final progression-free survival results will be presented from a Phase 2 clinical trial in patients with Stage 4 metastatic melanoma at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 5, 2010 in an oral presentation. The open-label multi-center clinical trial evaluated 3 dose regimens of Interleukin 21 (IL-21) in 40 patients with no prior systemic therapy for metastatic melanoma.

21 May 2010

Medical News

Phase III PRIMA study data of Rituxan to be featured at 46th ASCO

AFSPP program reduces suicide rates

Prescribing practices for dementia patients

Prodigy Diabetes Care honored with Export Achievement Certificate

Online health and wellness resource for libraries, educational institutions

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Genentech to present new data for targeted cancer medicines at 46th ASCO

Vesicoureteral reflux more common among girls

Volcano reports successful completion of cases with second generation OCT catheter and system

Clinical Infectious Diseases journal examines new scientific advances to curb HIV, TB epidemics

Americans divided over nation’s drug approval process

Infinity to present data from Hsp90 chaperone and Hedgehog pathway inhibitor programs at 2010 ASCO

VIA-2291 can reduce inflammation in patients with atherosclerosis: Study

Exelixis reports interim data from XL184 phase 2 trial for recurrent glioblastoma at ASCO 2010

More than 44% Canadian seniors living in residential care homes diagnosed with depression: CIHI study

Salix announces additional intellectual property protection for rifaximin in treatment of IBS

Restaurant Health Care Alliance launched to help restaurant employees gain access to health care coverage

Phase II study results of Lilly Oncology's tasisulam for metastatic melanoma to be presented at 46th ASCO

MSCRF awards grants to 42 projects under Maryland Stem Cell Research Act of 2006

ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Latest News